An Open-Label, Dose-Finding Study of Vedolizumab IV for Treatment of Steroid-Refractory Acute Intestinal Graft-Versus-Host Disease (GvHD) in Patients Who Have Undergone Allogeneic Hematopoietic Stem Cell Transplantation (Allo-HSCT)
Latest Information Update: 17 Sep 2021
At a glance
- Drugs Vedolizumab (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- Sponsors Takeda Oncology
- 09 Jun 2021 Primary endpoint (Percentage of Participants With Overall Response (Partial Response [PR]+Very Good Partial Response [VGPR]+Complete Response [CR]) at Day 28) has not been met, as results published in the Bone Marrow Transplantation.
- 09 Jun 2021 Results published in the Bone Marrow Transplantation
- 26 Jun 2018 Status changed from recruiting to discontinued.